# FDA 483 - Homayoon (nmi) Khanlou, M.D. - August 18, 2017

Source: https://www.globalkeysolutions.net/records/483/homayoon-nmi-khanlou-md/9fd52fa3-cb5f-437e-a38a-f5a9ee6460a3

> FDA 483 for Homayoon (nmi) Khanlou, M.D. on August 18, 2017. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Homayoon (nmi) Khanlou, M.D.
- Inspection Date: 2017-08-18
- Product Type: other
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: Honyoon (nmi) Khanlou, M.D. in Beverly Hills, CA, was inspected and cited for significant protocol deviations during clinical investigations. The inspection revealed failures to conduct required physical exams, ECGs, and questionnaires, as well as issues with maintaining accurate case histories. These findings indicate a lack of adherence to the investigational plan and proper documentation practices.

## Related Officers

- [investigator](https://www.globalkeysolutions.net/people/yvonne-lacour-davis/cf2434a3-26fc-4506-9476-ffe1af0db513)

Company: https://www.globalkeysolutions.net/companies/homayoon-nmi-khanlou-md/02957314-ae8c-42a4-bbbe-7174a77e3deb

Office: https://www.globalkeysolutions.net/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6